Multicenter Retrospective Study of Neurostimulation With Exit of Therapy by Explant

New Technologies and Applications in Sacral Neuromodulation: An Update

“…In a survey of 30 patients with movement disorders visiting a pre-DBS clinic (mean age 65, range 45-79 years), 63% chose the recharge-free device compared to 37% for the rechargeable device, even though the battery longevity of the recharge-free device was estimated at only 3-5 years [22]. In a multicenter, retrospective study with 352 explanted SCS patients it was reported that patients with rechargeable devices terminated their therapy earlier than patients with recharge-free devices [23]. This observation may be consistent with an increased burden for therapy maintenance, which could be related to a higher probability of device removal [23].…”

The Neuromodulation Appropriateness Consensus Committee on Best Practices for Dorsal Root Ganglion Stimulation

“…Recent reviews of explant data also examined the potential reasons for device explantation. Pope and colleagues in their retrospective review of 352 SCS cases found that 43.9% (152/346) of explants occurred due to failure or lack of efficacy , and Van Buyten et al in a study of more than 900 patients, found that 50% of the devices were explanted due to therapeutic failure . These failures of device may suggest the need for different approaches, specifically with traditionally difficult pain patterns and regions.…”

“…explants occurred due to failure or lack of efficacy (14), and Van Buyten et al in a study of more than 900 patients, found that 50% of the devices were explanted due to therapeutic failure (2). These failures of device may suggest the need for different approaches, specifically with traditionally difficult pain patterns and regions.…”

Redefining Success: Longitudinal Patient Reported Outcome Measures and the Importance of Psychometric Testing for Optimization in Neuromodulation

“…That said, challenges remain to better measure efficacy in a more objective manner. Currently, we still have some patients even after adequate trialing that struggle with long-term efficacy as demonstrated through the reported rate of device failures leading to explant as 20-30% of permanent implants (4). Often, patients explanted have a tenure of therapy less than 18 months (4).…”